The pan-ErbB receptor tyrosine kinase inhibitor canertinib induces ErbB-independent apoptosis in human leukemia (HL-60 and U-937) cells

Biochemical and Biophysical Research Communications

Volumn 393, Issue 1, 2010, Pages 6-10

  Trinks, Cecilia ^a   Djerf, Emelie A ^a   Hallbeck, Anna Lotta ^a   Jönsson, Jan Ingvar ^a   Walz, Thomas M ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Apoptosis; CI 1033; ErbB receptor; Growth inhibition; Leukemia; Tyrosine kinase inhibitor

Indexed keywords

CANERTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; LIPOCORTIN 5;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL STRAIN HL 60; CELL STRAIN U937; DOSE RESPONSE; DRUG EFFICACY; DRUG INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; LEUKEMIA; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; G1 PHASE; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MORPHOLINES; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN KINASE INHIBITORS; RECEPTOR, ERBB-2;

EID: 77249119638     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.01.055     Document Type: Article

References (22)

1. Schimmer A.D. Novel therapies targeting the apoptosis pathway for the treatment of acute myeloid leukemia. Curr. Treat. Options Oncol. 8 (2007) 277-286
2. Huang M.E., Ye Y.C., Chen S.R., Chai J.R., Lu J.X., Zhoa L., Gu L.J., and Wang Z.Y. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72 (1988) 567-572
3. Steeghs N., Nortier J.W., and Gelderblom H. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann. Surg. Oncol. 14 (2007) 942-953
4. Gora-Tybor J., and Robak T. Targeted drugs in chronic myeloid leukemia. Curr. Med. Chem. 15 (2008) 3036-3051
5. Perl A.E., and Carroll M. Exploiting signal transduction pathways in acute myelogenous leukemia. Curr. Treat. Options Oncol. 8 (2007) 265-276
6. Lindhagen E., Eriksson A., Wickström M., Danielsson K., Grundmark B., Henriksson R., Nygren P., Aleskog A., Larsson R., and Höglund M. Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia. Eur. J. Haematol. 81 (2008) 344-353
7. Stegmaier K., Corsello S.M., Ross K.N., Wong J.S., Deangelo D.J., and Golub T.R. Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood 106 (2005) 2841-2848
8. Moon D.O., Kim M.O., Lee J.D., Choi Y.H., Lee M.K., and Kim G.Y. Molecular mechanisms of ZD1839 (Iressa)-induced apoptosis in human leukemic U937 cells. Acta Pharmacol. Sin. 28 (2007) 1205-1214
9. Boehrer S., Ades L., Braun T., Galluzzi L., Grosjean J., Fabre C., Le Roux G., Gardin C., Martin A., de Botton S., Fenaux P., and Kroemer G. Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study. Blood 111 (2008) 2170-2180
10. Smaill J.B., Palmer B.D., Rewcastle G.W., Denny W.A., McNamara D.J., Dobrusin E.M., Bridges A.J., Zhou H., Showalter H.D., Winters R.T., Leopold W.R., Fry D.W., Nelson J.M., Slintak V., Elliot W.L., Roberts B.J., Vincent P.W., and Patmore S.J. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor. J. Med. Chem. 42 (1999) 1803-1815
11. Slichenmyer W.J., Elliott W.L., and Fry D.W. CI-1033, a pan-erbB tyrosine kinase inhibitor. Semin. Oncol. 28 (2001) 80-85
12. Öberg F., Hult N., Bjare U., Ivhed I., Kivi S., Bergh J., Larsson L.G., Sundstrom C., and Nilsson K. Characterization of a U-937 subline which can be induced to differentiate in serum-free medium. Int. J. Cancer 50 (1992) 153-160
13. Djerf E.A., Trinks C., Abdiu A., Thunell L.K., Hallbeck A.L., and Walz T.M. ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839). Melanoma Res. 19 (2009) 156-166
14. Vindelov L.L., Christensen I.J., and Nissen N.I. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3 (1983) 323-327
15. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
16. Mahtouk K., Jourdan M., De Vos J., Hertogh C., Fiol G., Jourdan E., Rossi J.F., and Klein B. An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis. Blood 103 (2004) 1829-1837
17. Moasser M.M., Basso A., Averbuch S.D., and Rosen N. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 61 (2001) 7184-7188
18. Vinante F., Rigo A., Papini E., Cassatella M.A., and Pizzolo G. Heparin-binding epidermal growth factor-like growth factor/diphtheria toxin receptor expression by acute myeloid leukemia cells. Blood 93 (1999) 1715-1723
19. Elenius K., Choi C.J., Paul S., Santiestevan E., Nishi E., and Klagsbrun M. Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase. Oncogene 18 (1999) 2607-2615
20. Maatta J.A., Sundvall M., Junttila T.T., Peri L., Laine V.J., Isola J., Egeblad M., and Elenius K. Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. Mol. Biol. Cell 17 (2006) 67-79
21. Baulida J., and Carpenter G. Heregulin degradation in the absence of rapid receptor-mediated internalization. Exp. Cell Res. 232 (1997) 167-172
22. Tikhomirov O., and Carpenter G. Identification of ErbB-2 kinase domain motifs required for geldanamycin-induced degradation. Cancer Res. 63 (2003) 39-43